MedTrace Logo

Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy

NCT02012608 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-05-29

Study results available
· View outcomes & findings →

Summary

This study is a single-centered, double-blind, two-arm randomized study to determine if oral glutamine will reduce radiation toxicity for the subjects undergoing Breast Conserving Therapy.

Conditions

Interventions

DRUG

Glutamine

Oral glutamine for subjects undergoing breast conserving therapy

DRUG

Placebo

For subjects undergoing breast conserving therapy

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Loverd Peacock, MD · University of Arkansas

  • Yihong Kaufmann, PhD · University of Arkansas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02012608 on ClinicalTrials.gov